Elan AIDS drug
Irish firm to begin IND studies to evaluate EL 10 in HIV-infected subjects. First study of the oral copolymer adsorbate of DHEA is expected to begin shortly in San Francisco. A placebo-controlled trial is in progress in Amsterdam, and discussion with Canadian authorities have taken place regarding the initiation of two multicenter studies in that country early next year. Elan is developing the compound for AIDS under an exclusive license from Colthurst Ltd....
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.